Literature DB >> 640344

Oral 25-hydroxyvitain D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy.

J E Compston, L W Horton.   

Abstract

Severe histological osteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of cholestyramine therapy. Treatment with oral 25-hydroxyvitamin D3, 50 microgram daily, produced marked biochemical, radiological, and histological improvement after 6 months. It is suggested that cholestyramine, by reducing vitamin D absorption, precipitated the rapid development of osteomalacia in this patient. This case report emphasizes the importance of routine vitamin D supplementation in all patients on long term cholestyramine therapy, and indicates that even in patients with small intestinal disease or resection, oral preparations of vitamin D or its metabolities and analogues may be effective.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 640344

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

1.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 2.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.

Authors:  J E Compston
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

3.  Thoughts on the aetiology of vitamin D deficiency in Asians.

Authors:  D A Heath
Journal:  Postgrad Med J       Date:  1983-10       Impact factor: 2.401

Review 4.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb

5.  Vitamin D status in Crohn's disease: association with nutrition and disease activity.

Authors:  A D Harries; R Brown; R V Heatley; L A Williams; S Woodhead; J Rhodes
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.